- Home
- HLN
as of 12-04-2025 3:57pm EST
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
| Founded: | 2022 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 41.7B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 8.9M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 0.23 | EPS Growth: | 41.64 |
| 52 Week Low/High: | $8.71 - $11.42 | Next Earning Date: | 07-31-2025 |
| Revenue: | $15,096,588,575 | Revenue Growth: | -2.12% |
| Revenue Growth (this year): | 1.51% | Revenue Growth (next year): | 4.67% |
AI-Powered HLN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare HLN vs Leading Stocks
See how HLN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HLN Haleon plc (Each representing two) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.